dc.contributor.author | Goedert, J. J. | en |
dc.contributor.author | O'Brien, T. R. | en |
dc.contributor.author | Hatzakis, Angelos E. | en |
dc.contributor.author | Kostrikis, Leontios G. | en |
dc.creator | Goedert, J. J. | en |
dc.creator | O'Brien, T. R. | en |
dc.creator | Hatzakis, Angelos E. | en |
dc.creator | Kostrikis, Leontios G. | en |
dc.date.accessioned | 2019-11-04T12:50:39Z | |
dc.date.available | 2019-11-04T12:50:39Z | |
dc.date.issued | 2001 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/53109 | |
dc.description.abstract | Objective: To determine whether improved prediction of AIDS-free survival following HIV-1 seroconversion is achieved by measuring HIV-1 2-LTR episomal DNA (2-LTR) circles and T cell receptor rearrangement excision circles (TREC), reflecting HIV replication and lymphocyte emigration from the thymus, respectively. Design: Subanalysis of a cohort of 154 patients with hemophilia who became HIV positive between 1978 and 1985 and were followed prospectively. Methods: Relative hazards (RH) of AIDS, in the absence of highly effective anti-HIV therapy, were estimated for age, HIV-1 viral load, CD4 lymphocyte count and levels of HIV-1 2-LTR circles and TREC [per 106 peripheral blood mononuclear cells (PBMC)]. Results: TREC correlated significantly with CD4 cell counts (r = 0.30) and age (r = -0.60). 2-LTR circles correlated significantly with HIV-1 viral load (r = 0.35). If viral load, CD4 lymphocytes and age were included in a proportional hazards model, the risk of AIDS during a median of 11.6 years of follow-up was increased significantly with fewer TREC (adjusted RH, 2.0 per log10 copies/106 PBMC) and more 2-LTR circles (RH, 1.7 per log10 copies/106 PBMC). AIDS prediction with TREC and 2-LTR circles held for most subgroups defined by median viral load, CD4 lymphocytes and age. Conclusions: PBMC that have high levels of HIV-1 replication and low levels of recent thymic emigrants are associated with a substantially increased risk of AIDS. It is not known if measurement of either TREC or 2-LTR circles will complement HIV-1 viral load as an estimation of the risk of AIDS for patients who are receiving highly effective anti-HIV therapy. © 2001 Lippincott Williams & Wilkins. | en |
dc.source | AIDS | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035941402&doi=10.1097%2f00002030-200111230-00005&partnerID=40&md5=28861a95a583eb085b9b07c6c580be0b | |
dc.subject | article | en |
dc.subject | Adult | en |
dc.subject | Humans | en |
dc.subject | Predictive Value of Tests | en |
dc.subject | priority journal | en |
dc.subject | Aging | en |
dc.subject | Risk Factors | en |
dc.subject | incidence | en |
dc.subject | Follow-Up Studies | en |
dc.subject | unclassified drug | en |
dc.subject | nonhuman | en |
dc.subject | T lymphocyte | en |
dc.subject | cohort analysis | en |
dc.subject | infection risk | en |
dc.subject | lymphocyte count | en |
dc.subject | virus load | en |
dc.subject | Acquired Immunodeficiency Syndrome | en |
dc.subject | Viral Load | en |
dc.subject | HIV Seropositivity | en |
dc.subject | Proportional Hazards Models | en |
dc.subject | Cohort Studies | en |
dc.subject | mononuclear cell | en |
dc.subject | Human immunodeficiency virus 1 | en |
dc.subject | HIV-1 | en |
dc.subject | virus replication | en |
dc.subject | acquired immune deficiency syndrome | en |
dc.subject | seroconversion | en |
dc.subject | DNA, Viral | en |
dc.subject | long terminal repeat | en |
dc.subject | AIDS incidence | en |
dc.subject | CD4 Lymphocyte Count | en |
dc.subject | Hemophilia | en |
dc.subject | HIV Long Terminal Repeat | en |
dc.subject | HIV-1 replication | en |
dc.subject | lymphocyte migration | en |
dc.subject | Prospective cohort study | en |
dc.subject | Receptors, Antigen, T-Cell | en |
dc.subject | t cell receptor rearrangement excision DNA circle | en |
dc.subject | T lymphocyte receptor | en |
dc.subject | T-cell production | en |
dc.title | T cell receptor excision circles and HIV-1 2-LTR episomal DNA to predict AIDS in patients not receiving effective therapy | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1097/00002030-200111230-00005 | |
dc.description.volume | 15 | |
dc.description.startingpage | 2245 | |
dc.description.endingpage | 2250 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Cited By :11</p> | en |
dc.source.abbreviation | AIDS | en |
dc.contributor.orcid | Kostrikis, Leontios G. [0000-0002-5340-7109] | |
dc.gnosis.orcid | 0000-0002-5340-7109 | |